178 related articles for article (PubMed ID: 28528134)
1. Enhancing Tumor Cell Response to Multidrug Resistance with pH-Sensitive Quercetin and Doxorubicin Conjugated Multifunctional Nanoparticles.
Daglioglu C
Colloids Surf B Biointerfaces; 2017 Aug; 156():175-185. PubMed ID: 28528134
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Characterization of AICAR and DOX Conjugated Multifunctional Nanoparticles as a Platform for Synergistic Inhibition of Cancer Cell Growth.
Daglioglu C; Okutucu B
Bioconjug Chem; 2016 Apr; 27(4):1098-111. PubMed ID: 26996194
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effects of AICAR and DOX Conjugated Multifunctional Nanoparticles in Sensitization and Elimination of Cancer Cells via Survivin Targeting.
Daglioglu C; Okutucu B
Pharm Res; 2017 Jan; 34(1):175-184. PubMed ID: 27783307
[TBL] [Abstract][Full Text] [Related]
4. Environmentally Responsive Dual-Targeting Nanoparticles: Improving Drug Accumulation in Cancer Cells as a Way of Preventing Anticancer Drug Efflux.
Daglioglu C
J Pharm Sci; 2018 Mar; 107(3):934-941. PubMed ID: 29107049
[TBL] [Abstract][Full Text] [Related]
5. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
[TBL] [Abstract][Full Text] [Related]
6. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.
Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704
[TBL] [Abstract][Full Text] [Related]
7. Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors.
Ramasamy T; Ruttala HB; Chitrapriya N; Poudal BK; Choi JY; Kim ST; Youn YS; Ku SK; Choi HG; Yong CS; Kim JO
Acta Biomater; 2017 Jan; 48():131-143. PubMed ID: 27794477
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells.
Zhang Z; Xu S; Wang Y; Yu Y; Li F; Zhu H; Shen Y; Huang S; Guo S
J Colloid Interface Sci; 2018 Jan; 509():47-57. PubMed ID: 28881205
[TBL] [Abstract][Full Text] [Related]
10. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
11. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
12. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer.
Han NN; Li X; Tao L; Zhou Q
Biochem Biophys Res Commun; 2018 Mar; 498(1):178-185. PubMed ID: 29317204
[TBL] [Abstract][Full Text] [Related]
14. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin.
Chen Y; Tezcan O; Li D; Beztsinna N; Lou B; Etrych T; Ulbrich K; Metselaar JM; Lammers T; Hennink WE
Nanoscale; 2017 Jul; 9(29):10404-10419. PubMed ID: 28702658
[TBL] [Abstract][Full Text] [Related]
17. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
18. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
20. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
